WP
RYTM icon

Woodline Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

Woodline Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.3M Hold
758,891
– – 0.26% 91
2026
Q1 		$66M Buy
758,891
+70,112
+10% +$6.82M 0.25% 92
2025
Q4 		$73.7M Buy
688,779
+108,596
+19% +$11.5M 0.29% 76
2025
Q3 		$58.6M Buy
580,183
+65,802
+13% +$6.11M 0.28% 85
2025
Q2 		$32.5M Buy
+514,381
New +$31.5M 0.17% 169
2024
Q4 		– Sell
-143,823
Closed -$7.53M – 987
2024
Q3 		$7.53M Buy
143,823
+99,576
+225% +$4.77M 0.06% 338
2024
Q2 		$1.82M Sell
44,247
-127,960
-74% -$5.11M 0.02% 427
2024
Q1 		$7.46M Buy
172,207
+97,357
+130% +$4.26M 0.07% 312
2023
Q4 		$3.44M Buy
+74,850
New +$2.36M 0.04% 349

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Woodline Partners's RYTM Position: Q2 2026 in Review

Woodline Partners held its Rhythm Pharmaceuticals (RYTM) position steady in Q2 2026 at 758,891 shares worth $84.3M. The position accounts for 0.26% of the portfolio, ranked #91.

Woodline Partners first reported a position in RYTM in Q4 2023 and has held it in 9 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Woodline Partners held 758,891 shares of Rhythm Pharmaceuticals worth $84.3M as of Q2 2026.
  • Woodline Partners left its Rhythm Pharmaceuticals share count unchanged in Q2 2026.
  • Rhythm Pharmaceuticals made up 0.26% of Woodline Partners's portfolio in Q2 2026, its #91 holding.
  • Woodline Partners first reported a position in Rhythm Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.